Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
1.430 ^USD	-0.69%		-13.33%	-4.03%

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Marker Therapeutics, Inc. announced that it has received $16.1 million in funding

Published on 12/22/2024

S&P Capital IQ

MARKER THERAPEUTICS, INC.

-0.69%

On December 23, 2024. Marker Therapeutics, Inc. closed the transaction.The company will issue securities pursuant to exemption provided under Regulation D. The transaction included participation from five investors.

Latest news about Marker Therapeutics, Inc.

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	Marker Therapeutics, Inc. Appoints Kathryn Penkus Corzo to Board of Directors, Effective November 1, 2025	CI
11-05	Marker Therapeutics appoints Kathryn Penkus Corzo to board of directors	RE
11-03	Marker Therapeutics, Inc. Announces Data from Phase 1 APOLLO Study to Present in Two Posters at 67Th American Society of Hematology Annual Meeting and Exposition	CI
06/10/25	Marker Therapeutics, Inc. Announces First Patient Treated in Off-The-Shelf Program	CI
26/08/25	Marker Therapeutics, Inc. - Special Call
26/08/25	Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study	MT
14/08/25	Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
29/05/25	Marker Therapeutics, Inc. - Special Call
20/05/25	Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	CI
20/05/25	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	RE
15/05/25	Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/03/25	Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
30/03/25	Marker Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

Chart Marker Therapeutics, Inc.

Duration

Period

MRKR: Dynamic Chart

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-11 - Q4 2025 Earnings Release (Projected)

More about the company